Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
The video in this section is a copy of a recorded webinar organized by Shionogi to launch cefiderocol to the UK market in September 2020. Dr Andreas Karas presents the key clinical data for this new antibiotic for MDR Gram-negative infections, followed by reflections from Professor Jonathan Edgeworth on the potential use of the new agent in UK clinical practice. Included in the latter is a case study example of a compassionate use case using cefiderocol.
Identifiants
pubmed: 34223150
doi: 10.1093/jacamr/dlab053
pii: dlab053
pmc: PMC8251257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
i17Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.